doi:10.3969/j.issn.1674-490X.2019.06.003

Abstract

Abstract: Beta-defensins are recently discovered in the oral cavity as biogenic small molecular polypeptides, which can be widely detected in normal and pathological oral mucosa. They have the advantages of broad spectrum of antimicrobial activities, strong antimicrobial activity and prominent immune regulation ability, and play a unique role in oral local immune defense. In vivo and in vitro studies beta-defensin has significant inhibitory effect on a variety of periodontal pathogens, and with the progress of periodontitis, there are significant differences in the expression of beta-defensin in gingival tissue and gingival crevicular fluid, which indicates that it plays a key role in the development of periodontal diseases and the maintenance of periodontal homeostasis. This article elaborates the research progress of beta defensin and periodontitis prevention and treatment.

Key words: beta defensin, periodontitis, antibiotics, immunity, prevention and treatment

CLC Number:

References

[1] ABUSLEME L, DUPUY A K, DUTZAN N, et al. The subgingival microbiome in health and periodontitis and its relationship with community biomass and inflammation[J]. ISME J, 2013, 7(5): 1016-1025. DOI: 10.1038/ismej.2012.174.
[2] CHOI J, SEYMOUR G J. Vaccines against periodontitis: a forward-looking review[J]. J Periodontal Implant Sci, 2010, 40(4): 153. DOI: 10.5051/jpis.2010.40.4.153.
[3] SOUTHERLAND J H, TAYLOR G W, MOSS K, et al. Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease[J]. Periodontol, 2000, 2006, 40(1): 130-143. DOI: 10.1111/j.1600-0757.2005.00138.x.
[4] LI X, KOLLTVEIT K M, TRONSTAD L, et al. Systemic diseases caused by oral infection[J]. Clin Microbiol Rev, 2000, 13(4): 547-558. DOI: 10.1128/cmr.13.4.547-558.2000.
[5] PIZZO G, GUIGLIA R, RUSSO L L, et al. Dentistry and internal medicine: from the focal infection theory to the periodontal medicine concept[J]. Eur J Intern Med, 2010, 21(6): 496-502. DOI: 10.1016/j.ejim.2010.07.011.
[6] BENSCH K W, RAIDA M, MÄGERT H, et al. hBD-1: a novel β-defensin from human plasma[J]. FEBS Lett, 1995, 368(2): 331-335. DOI: 10.1016/0014-5793(95)00687-5.
[7] HARDER J, BARTELS J, CHRISTOPHERS E, et al. A peptide antibiotic from human skin[J]. Nature, 1997, 387(6636): 861. DOI: 10.1038/43088.
[8] HARDER J, BARTELS J, CHRISTOPHERS E, et al. Isolation and characterization of human β-defensin-3, a novel human inducible peptide antibiotic[J]. J Biol Chem, 2001, 276(8): 5707-5713. DOI: 10.1074/jbc.m008557200.
[9] HUTTNER K M, BEVINS C L. Antimicrobial peptides as mediators of epithelial host defense[J]. Pediatr Res, 1999, 45(6): 785-794. DOI: 10.1203/00006450-199906000-00001.
[10] OKUMURA K. Cathelicidins: Therapeutic antimicrobial and antitumor host defense peptides for oral diseases[J]. Jpn Dent Sci Rev, 2011, 47(1): 67-81. DOI: 10.1016/j.jdsr.2010.11.001.
[11] YANG D, BIRAGYN A, KWAK L W, et al. Mammalian defensins in immunity: more than just microbicidal[J]. Trends Immunol, 2002, 23(6): 291-296. DOI: 10.1016/s1471-4906(02)02246-9.
[12] SUGIARTO H, YU P. Avian antimicrobial peptides: the defense role of β-defensins[J]. Biochem Biophys Res Commun, 2004, 323(3): 721-727. DOI: 10.1016/j.bbrc.2004.08.162.
[13] KOHLGRAF K G, PINGEL L C, DIETRICH D E, et al. Defensins as anti-inflammatory compounds and mucosal adjuvants[J]. Futur Microbiol, 2010, 5(1): 99-113. DOI: 10.2217/fmb.09.104.
[14] YANG D, BIRAGYN A, HOOVER D M, et al. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense[J]. Annu Rev Immunol, 2004, 22(1): 181-215. DOI: 10.1146/annurev.immunol.22.012703.104603.
[15] SELSTED M E, OUELLETTE A J. Mammalian defensins in the antimicrobial immune response[J]. Nat Immunol, 2005, 6(6): 551-557. DOI: 10.1038/ni1206.
[16] DHOPLE V, KRUKEMEYER A, RAMAMOORTHY A. The human beta-defensin-3, an antibacterial peptide with multiple biological functions[J]. Biochim Et Biophys Acta BBA-Biomembr, 2006, 1758(9): 1499-1512. DOI: 10.1016/j.bbamem.2006.07.007.
[17] LEHRER R I, LICHTENSTEIN A K, GANZ T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells[J]. Annu Rev Immunol, 1993, 11(1): 105-128. DOI: 10.1146/annurev.iy.11.040193.000541.
[18] LEE J, JUNG S W, CHO A E. Molecular insights into the adsorption mechanism of human β-defensin-3 on bacterial membranes[J]. Langmuir, 2016, 32(7): 1782-1790. DOI: 10.1021/acs.langmuir.5b04113.
[19] HANCOCK R E W, LEHRER R. Cationic peptides: a new source of antibiotics[J]. Trends Biotechnol, 1998, 16(2): 82-88. DOI: 10.1016/s0167-7799(97)01156-6.
[20] LEE J, CHANG S W, PERINPANAYAGAM H, et al. Antibacterial efficacy of a human β-defensin-3 peptide on multispecies biofilms[J]. J Endod, 2013, 39(12): 1625-1629. DOI: 10.1016/j.joen.2013.07.035.
[21] ZHU C, TAN H L, CHENG T, et al. Human beta-defensin 3 inhibits antibiotic-resistant Staphylococcus biofilm formation[J]. J Surg Res, 2013,183(1):204-213.
[22] NIYONSABA F, IWABUCHI K, MATSUDA H, et al. Epithelial cell-derived human β-defensin-2 Acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway[J]. Int Immunol, 2002, 14(4): 421-426. DOI: 10.1093/intimm/14.4.421.
[23] FUNDERBURG N, LEDERMAN M M, FENG Z, et al. Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2[J]. Proc Natl Acad Sci U S A, 2007, 104(47): 18631-18635. DOI: 10.1073/pnas.0702130104.
[24] BIRAGYN A, RUFFINI P A, LEIFER C A, et al. Toll-like receptor 4-dependent activation of dendritic cells by -defensin 2[J]. Science, 2002, 298(5595): 1025-1029. DOI: 10.1126/science.1075565.
[25] MEANS T K, GOLENBOCK D T, FENTON M J. The biology of Toll-like receptors[J]. Cytokine Growth Factor Rev, 2000, 11(3): 219-232. DOI: 10.1016/s1359-6101(00)00006-x.
[26] GANZ T. Defensins: antimicrobial peptides of innate immunity[J]. Nat Rev Immunol, 2003, 3(9): 710-720. DOI: 10.1038/nri1180.
[27] LI X Y, DUAN D Y, YANG J M, et al. The expression of human β-defensins(hBD-1, hBD-2, hBD-3, hBD-4)in gingival epithelia[J]. Arch Oral Biol, 2016, 66: 15-21. DOI: 10.1016/j.archoralbio.2016.01.012.
[28] MATHEWS M, JIA H P, Guthmiller J M, et al. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands[J]. Infect Immun, 1999, 67(6): 2740-2745.
[29] KRISANAPRAKORNKIT S, WEINBERG A, PEREZ C N, et al. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue[J]. Infect Immun, 1998, 66(9):4222-4228.
[30] BURD R S, FURRER J L, SULLIVAN J, et al. Murine beta-defensin-3 is an inducible peptide with limited tissue expression and broad-spectrum antimicrobial activity[J]. Shock, 2002, 18(5): 461-464. DOI: 10.1097/00024382-200211000-00013.
[31] VANKEERBERGHEN A, NUYTTEN H, DIERICKX K, et al. Differential induction of human beta-defensin expression by periodontal commensals and pathogens in periodontal pocket epithelial cells[J]. J Periodontol, 2005, 76(8): 1293-1303. DOI: 10.1902/jop.2005.76.8.1293.
[32] LIU J R, CHEN J, DU X Y, et al. The expression of hBDs in the gingival tissue and keratinocytes from healthy subjects and periodontitis patients[J]. Arch Oral Biol, 2014, 59(2): 193-198. DOI: 10.1016/j.archoralbio.2013.11.007.
[33] VARDAR-SENGUL S, DEMIRCI T, SEN B H, et al. Human beta defensin-1 and -2 expression in the gingiva of patients with specific periodontal diseases[J]. J Periodontal Res, 2007, 42(5): 429-437. DOI: 10.1111/j.1600-0765.2006.00964.x.
[34] DOMMISCH H, ACIL Y, DUNSCHE A, et al. Differential gene expression of human beta-defensins(hBD-1, -2, -3)in inflammatory gingival diseases[J]. Oral Microbiol Immunol, 2005, 20(3): 186-190. DOI: 10.1111/j.1399-302x.2005.00211.x.
[35] PEREIRA A L, HOLZHAUSEN M, FRANCO G C N, et al. Human β-defensin 2 and protease activated receptor-2 expression in patients with chronic periodontitis[J]. Arch Oral Biol, 2012, 57(12): 1609-1614. DOI: 10.1016/j.archoralbio.2012.04.018.
[36] BRANCATISANO F L, MAISETTA G, BARSOTTI F, et al. Reduced human beta defensin 3 in individuals with periodontal disease[J]. J Dent Res, 2011, 90(2): 241-245. DOI: 10.1177/0022034510385686.
[37] EBRAHEM M A. Expression of human beta defensins(HBDs)1, 2 and 3 in gingival crevicular fluid of patients affected by localized aggressive periodontitis[J]. Saudi Dent J, 2013, 25(2): 75-82. DOI: 10.1016/j.sdentj.2013.02.004.
[38] 钟德钰, 杨美薷, 吴琦, 等. 人中性粒细胞防御素对龈下微生物的影响[J]. 华西口腔医学杂志, 1997, 15(2): 123-124.
[39] 杨再波,华炜,邹毅,等. 人 β 防御素应用于慢性牙周炎治疗的作用机制研究[J]. 临床口腔医学杂志, 2018, 34(12):711-714. DOI: 10.3969/j.issn.1003-1634.2018.12.003.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(6): 9-14.
[2]	XUE Juan,LIU Weihua,DUAN Fei,SUN Xiaofang,LI Shaochun,GUO Yongqing,LI Jian,LI Xiaoqing. Research progress of Chinese herb prevention and treatment of pulmonary ifbrosis at the molecular level [J]. Medical Reserch and Education, 2014, 31(1): 91-94.
[3]	CAO Lijun,YANG Jing,GENG Fengzhen,LI Huiqing,SHI Zheng,SHI Dongyan. Retrospective report of clinical characterizations of an Enterobacter cloacae carrying NDM-1 associated with urinary tract infection [J]. Medical Reserch and Education, 2014, 31(1): 33-36.